Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly ...

The average one-year price target for Adaptive Biotechnologies (NASDAQGS:ADPT) (MUN:1HM) has been revised to $28.05 / share. This is an increase of 11.11% from the prior estimate of $25.24 dated ...

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of ...

Adaptive Biotechnologies Corporation (ADPT) is down 3.5% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not fully clear, but the move appears ...

Learn more about whether Adaptive Biotechnologies Corporation or Fortrea Holdings Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Susan Bobulsky is identified as an officer of Adaptive Biotechnologies Corporation. Shares proposed for sale: 6,444 common ...

Frontier Biotech announced that RONGJIANLU (Lu Rongjian), a shareholder holding more than 5% of the company's shares, reduced ...

Guggenheimanalyst Subbu Nambi maintains $Adaptive Biotechnologies(ADPT.US)$ with a buy rating, and adjusts the target price ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stands at the forefront of the healthcare sector with its innovative approach to diagnostics and research. The Seattle-based company, which was ...

EPI-321 data show increased lean muscle volume and strength after six months in six people with FSHD. Read the full Phase I/II study results and updates.